UBE2T and cancer: For instance, studying more than 10,000 TCGA pan-cancer tumours, Wu and colleagues found that tumours with amplifications in DDR genes like UBE2T (Ubiquitin Conjugating Enzyme E2 T) exhibited significantly reduced mutation burden, temozolomide resistance, and worse patient survival.